Episode 9: Our Take May-Part 2

Episode Summary

To all of our listeners, we hope you had a wonderful Memorial Day Weekend! In this episode, John shares an abbreviated our take on the second part of May focused on FDA and CMS's take on lowering drug prices.

Episode Notes

To all of our listeners, we hope you had a wonderful Memorial Day Weekend! In this episode, John shares an an abbreviated our take on the second part of May focused on FDA and The Centers for Medicare and Medicaid Services' (CMS) take on lowering drug prices.

• Steps are being taken to lower drug prices—but which, if any, will work? The FDA posted a list of more than 50 drugs for which generic drugmakers have been unable to obtain samples of certain branded products from the manufacturers. CMS also weighed in last week by announcing enhanced “drug dashboards” that include year-over-year pricing changes for drugs reimbursed by Medicare Part B and Part D and Medicaid.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

‍